SIRT6 inhibits endothelial-to-mesenchymal transition through attenuating the vascular endothelial inflammatory response

2021 ◽  
Vol 101 ◽  
pp. 108240
Author(s):  
Lifang Chen ◽  
Guan Wang ◽  
Jianyu He ◽  
Xin Yang ◽  
Zihan Zheng ◽  
...  
2016 ◽  
Vol 310 (11) ◽  
pp. L1185-L1198 ◽  
Author(s):  
Toshio Suzuki ◽  
Yuji Tada ◽  
Rintaro Nishimura ◽  
Takeshi Kawasaki ◽  
Ayumi Sekine ◽  
...  

Pulmonary vascular endothelial function may be impaired by oxidative stress in endotoxemia-derived acute lung injury. Growing evidence suggests that endothelial-to-mesenchymal transition (EndMT) could play a pivotal role in various respiratory diseases; however, it remains unclear whether EndMT participates in the injury/repair process of septic acute lung injury. Here, we analyzed lipopolysaccharide (LPS)-treated mice whose total number of pulmonary vascular endothelial cells (PVECs) transiently decreased after production of reactive oxygen species (ROS), while the population of EndMT-PVECs significantly increased. NAD(P)H oxidase inhibition suppressed EndMT of PVECs. Most EndMT-PVECs derived from tissue-resident cells, not from bone marrow, as assessed by mice with chimeric bone marrow. Bromodeoxyuridine-incorporation assays revealed higher proliferation of capillary EndMT-PVECs. In addition, EndMT-PVECs strongly expressed c- kit and CD133. LPS loading to human lung microvascular endothelial cells (HMVEC-Ls) induced reversible EndMT, as evidenced by phenotypic recovery observed after removal of LPS. LPS-induced EndMT-HMVEC-Ls had increased vasculogenic ability, aldehyde dehydrogenase activity, and expression of drug resistance genes, which are also fundamental properties of progenitor cells. Taken together, our results demonstrate that LPS induces EndMT of tissue-resident PVECs during the early phase of acute lung injury, partly mediated by ROS, contributing to increased proliferation of PVECs.


2017 ◽  
Vol 104 (3) ◽  
pp. 932-939 ◽  
Author(s):  
Ben M.-W. Illigens ◽  
Alejandra Casar Berazaluce ◽  
Dimitrios Poutias ◽  
Robert Gasser ◽  
Pedro J. del Nido ◽  
...  

2015 ◽  
Vol 21 (16) ◽  
pp. 3716-3726 ◽  
Author(s):  
Seo-Hyun Choi ◽  
Zhen-Yu Hong ◽  
Jae-Kyung Nam ◽  
Hae-June Lee ◽  
Junho Jang ◽  
...  

2013 ◽  
Vol 210 (3) ◽  
pp. 563-579 ◽  
Author(s):  
Charlotte Anderberg ◽  
Sara I. Cunha ◽  
Zhenhua Zhai ◽  
Eliane Cortez ◽  
Evangelia Pardali ◽  
...  

Therapy-induced resistance remains a significant hurdle to achieve long-lasting responses and cures in cancer patients. We investigated the long-term consequences of genetically impaired angiogenesis by engineering multiple tumor models deprived of endoglin, a co-receptor for TGF-β in endothelial cells actively engaged in angiogenesis. Tumors from endoglin-deficient mice adapted to the weakened angiogenic response, and refractoriness to diminished endoglin signaling was accompanied by increased metastatic capability. Mechanistic studies in multiple mouse models of cancer revealed that deficiency for endoglin resulted in a tumor vasculature that displayed hallmarks of endothelial-to-mesenchymal transition, a process of previously unknown significance in cancer biology, but shown by us to be associated with a reduced capacity of the vasculature to avert tumor cell intra- and extravasation. Nevertheless, tumors deprived of endoglin exhibited a delayed onset of resistance to anti-VEGF (vascular endothelial growth factor) agents, illustrating the therapeutic utility of combinatorial targeting of multiple angiogenic pathways for the treatment of cancer.


Sign in / Sign up

Export Citation Format

Share Document